Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.
Identifieur interne : 001470 ( Main/Exploration ); précédent : 001469; suivant : 001471Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.
Auteurs : José María Aguado [Espagne] ; Julián Torre-Cisneros ; Jesús Fortún ; Natividad Benito ; Yolanda Meije ; Antonio Doblas ; Patricia Mu OzSource :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2009.
Descripteurs français
- KwdFr :
- Antituberculeux (administration et posologie), Antituberculeux (usage thérapeutique), Espagne (MeSH), Humains (MeSH), Immunosuppresseurs (effets indésirables), Immunosuppresseurs (usage thérapeutique), Interactions médicamenteuses (MeSH), Rifampicine (administration et posologie), Rifampicine (usage thérapeutique), Transplantation (MeSH), Transplantation d'organe (effets indésirables), Tuberculose (mortalité), Tuberculose (traitement médicamenteux), Tuberculose (épidémiologie).
- MESH :
- administration et posologie : Antituberculeux, Rifampicine.
- effets indésirables : Immunosuppresseurs, Transplantation d'organe.
- mortalité : Tuberculose.
- traitement médicamenteux : Tuberculose.
- usage thérapeutique : Antituberculeux, Immunosuppresseurs, Rifampicine.
- épidémiologie : Tuberculose.
- Espagne, Humains, Interactions médicamenteuses, Transplantation.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Antitubercular Agents (administration & dosage), Antitubercular Agents (therapeutic use), Drug Interactions (MeSH), Humans (MeSH), Immunosuppressive Agents (adverse effects), Immunosuppressive Agents (therapeutic use), Organ Transplantation (adverse effects), Rifampin (administration & dosage), Rifampin (therapeutic use), Spain (MeSH), Transplantation (MeSH), Tuberculosis (drug therapy), Tuberculosis (epidemiology), Tuberculosis (mortality).
- MESH :
- chemical , administration & dosage : Antitubercular Agents, Rifampin.
- chemical , adverse effects : Immunosuppressive Agents.
- chemical , therapeutic use : Antitubercular Agents, Immunosuppressive Agents, Rifampin.
- geographic : Spain.
- adverse effects : Organ Transplantation.
- drug therapy : Tuberculosis.
- epidemiology : Tuberculosis.
- mortality : Tuberculosis.
- Drug Interactions, Humans, Transplantation.
Abstract
Tuberculosis is a particularly important condition in solid-organ transplant recipients because of the delay in treatment caused by the difficulties involved in its diagnosis and because of the pharmacological toxicity associated with this treatment. Both treatment delay and toxicity are responsible for the many clinical complications of and high mortality associated with tuberculosis in this population. The Consensus Statement from the Spanish Group for the Study of Infectious Diseases in Transplant Recipients defines the indications for treatment of latent tuberculosis infection in solid-organ transplant recipients, especially in patients with a high risk of pharmacological toxicity, as is the case with liver recipients. We established a series of recommendations regarding the types of drugs and the duration of treatment of tuberculosis in solid-organ recipients, giving special attention to pharmacological interactions between rifampin and immunosuppressive drugs (cyclosporine, tacrolimus, rapamycin, and corticosteroids).
DOI: 10.1086/597590
PubMed: 19320593
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.</title><author><name sortKey="Aguado, Jose Maria" sort="Aguado, Jose Maria" uniqKey="Aguado J" first="José María" last="Aguado">José María Aguado</name><affiliation wicri:level="3"><nlm:affiliation>Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Torre Cisneros, Julian" sort="Torre Cisneros, Julian" uniqKey="Torre Cisneros J" first="Julián" last="Torre-Cisneros">Julián Torre-Cisneros</name></author><author><name sortKey="Fortun, Jesus" sort="Fortun, Jesus" uniqKey="Fortun J" first="Jesús" last="Fortún">Jesús Fortún</name></author><author><name sortKey="Benito, Natividad" sort="Benito, Natividad" uniqKey="Benito N" first="Natividad" last="Benito">Natividad Benito</name></author><author><name sortKey="Meije, Yolanda" sort="Meije, Yolanda" uniqKey="Meije Y" first="Yolanda" last="Meije">Yolanda Meije</name></author><author><name sortKey="Doblas, Antonio" sort="Doblas, Antonio" uniqKey="Doblas A" first="Antonio" last="Doblas">Antonio Doblas</name></author><author><name sortKey="Mu Oz, Patricia" sort="Mu Oz, Patricia" uniqKey="Mu Oz P" first="Patricia" last="Mu Oz">Patricia Mu Oz</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19320593</idno><idno type="pmid">19320593</idno><idno type="doi">10.1086/597590</idno><idno type="wicri:Area/Main/Corpus">001526</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001526</idno><idno type="wicri:Area/Main/Curation">001526</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001526</idno><idno type="wicri:Area/Main/Exploration">001526</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.</title><author><name sortKey="Aguado, Jose Maria" sort="Aguado, Jose Maria" uniqKey="Aguado J" first="José María" last="Aguado">José María Aguado</name><affiliation wicri:level="3"><nlm:affiliation>Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Torre Cisneros, Julian" sort="Torre Cisneros, Julian" uniqKey="Torre Cisneros J" first="Julián" last="Torre-Cisneros">Julián Torre-Cisneros</name></author><author><name sortKey="Fortun, Jesus" sort="Fortun, Jesus" uniqKey="Fortun J" first="Jesús" last="Fortún">Jesús Fortún</name></author><author><name sortKey="Benito, Natividad" sort="Benito, Natividad" uniqKey="Benito N" first="Natividad" last="Benito">Natividad Benito</name></author><author><name sortKey="Meije, Yolanda" sort="Meije, Yolanda" uniqKey="Meije Y" first="Yolanda" last="Meije">Yolanda Meije</name></author><author><name sortKey="Doblas, Antonio" sort="Doblas, Antonio" uniqKey="Doblas A" first="Antonio" last="Doblas">Antonio Doblas</name></author><author><name sortKey="Mu Oz, Patricia" sort="Mu Oz, Patricia" uniqKey="Mu Oz P" first="Patricia" last="Mu Oz">Patricia Mu Oz</name></author></analytic><series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title><idno type="eISSN">1537-6591</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antitubercular Agents (administration & dosage)</term><term>Antitubercular Agents (therapeutic use)</term><term>Drug Interactions (MeSH)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (adverse effects)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Organ Transplantation (adverse effects)</term><term>Rifampin (administration & dosage)</term><term>Rifampin (therapeutic use)</term><term>Spain (MeSH)</term><term>Transplantation (MeSH)</term><term>Tuberculosis (drug therapy)</term><term>Tuberculosis (epidemiology)</term><term>Tuberculosis (mortality)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antituberculeux (administration et posologie)</term><term>Antituberculeux (usage thérapeutique)</term><term>Espagne (MeSH)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (effets indésirables)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Interactions médicamenteuses (MeSH)</term><term>Rifampicine (administration et posologie)</term><term>Rifampicine (usage thérapeutique)</term><term>Transplantation (MeSH)</term><term>Transplantation d'organe (effets indésirables)</term><term>Tuberculose (mortalité)</term><term>Tuberculose (traitement médicamenteux)</term><term>Tuberculose (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antitubercular Agents</term><term>Rifampin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antitubercular Agents</term><term>Immunosuppressive Agents</term><term>Rifampin</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antituberculeux</term><term>Rifampicine</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Organ Transplantation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Immunosuppresseurs</term><term>Transplantation d'organe</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antituberculeux</term><term>Immunosuppresseurs</term><term>Rifampicine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Tuberculose</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Interactions</term><term>Humans</term><term>Transplantation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Espagne</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Transplantation</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tuberculosis is a particularly important condition in solid-organ transplant recipients because of the delay in treatment caused by the difficulties involved in its diagnosis and because of the pharmacological toxicity associated with this treatment. Both treatment delay and toxicity are responsible for the many clinical complications of and high mortality associated with tuberculosis in this population. The Consensus Statement from the Spanish Group for the Study of Infectious Diseases in Transplant Recipients defines the indications for treatment of latent tuberculosis infection in solid-organ transplant recipients, especially in patients with a high risk of pharmacological toxicity, as is the case with liver recipients. We established a series of recommendations regarding the types of drugs and the duration of treatment of tuberculosis in solid-organ recipients, giving special attention to pharmacological interactions between rifampin and immunosuppressive drugs (cyclosporine, tacrolimus, rapamycin, and corticosteroids).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19320593</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>9</Issue><PubDate><Year>2009</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.</ArticleTitle><Pagination><MedlinePgn>1276-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1086/597590</ELocationID><Abstract><AbstractText>Tuberculosis is a particularly important condition in solid-organ transplant recipients because of the delay in treatment caused by the difficulties involved in its diagnosis and because of the pharmacological toxicity associated with this treatment. Both treatment delay and toxicity are responsible for the many clinical complications of and high mortality associated with tuberculosis in this population. The Consensus Statement from the Spanish Group for the Study of Infectious Diseases in Transplant Recipients defines the indications for treatment of latent tuberculosis infection in solid-organ transplant recipients, especially in patients with a high risk of pharmacological toxicity, as is the case with liver recipients. We established a series of recommendations regarding the types of drugs and the duration of treatment of tuberculosis in solid-organ recipients, giving special attention to pharmacological interactions between rifampin and immunosuppressive drugs (cyclosporine, tacrolimus, rapamycin, and corticosteroids).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aguado</LastName><ForeName>José María</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torre-Cisneros</LastName><ForeName>Julián</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Fortún</LastName><ForeName>Jesús</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Benito</LastName><ForeName>Natividad</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Meije</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Doblas</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Muñoz</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>VJT6J7R4TR</RegistryNumber><NameOfSubstance UI="D012293">Rifampin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016377" MajorTopicYN="N">Organ Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012293" MajorTopicYN="N">Rifampin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014180" MajorTopicYN="N">Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="N">Tuberculosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19320593</ArticleId><ArticleId IdType="doi">10.1086/597590</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Communauté de Madrid</li></region><settlement><li>Madrid</li></settlement></list><tree><noCountry><name sortKey="Benito, Natividad" sort="Benito, Natividad" uniqKey="Benito N" first="Natividad" last="Benito">Natividad Benito</name><name sortKey="Doblas, Antonio" sort="Doblas, Antonio" uniqKey="Doblas A" first="Antonio" last="Doblas">Antonio Doblas</name><name sortKey="Fortun, Jesus" sort="Fortun, Jesus" uniqKey="Fortun J" first="Jesús" last="Fortún">Jesús Fortún</name><name sortKey="Meije, Yolanda" sort="Meije, Yolanda" uniqKey="Meije Y" first="Yolanda" last="Meije">Yolanda Meije</name><name sortKey="Mu Oz, Patricia" sort="Mu Oz, Patricia" uniqKey="Mu Oz P" first="Patricia" last="Mu Oz">Patricia Mu Oz</name><name sortKey="Torre Cisneros, Julian" sort="Torre Cisneros, Julian" uniqKey="Torre Cisneros J" first="Julián" last="Torre-Cisneros">Julián Torre-Cisneros</name></noCountry><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Aguado, Jose Maria" sort="Aguado, Jose Maria" uniqKey="Aguado J" first="José María" last="Aguado">José María Aguado</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001470 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001470 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19320593
|texte= Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19320593" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |